Class information for: |
Basic class information |
Class id | #P | Avg. number of references |
Database coverage of references |
---|---|---|---|
10431 | 1064 | 32.3 | 48% |
Hierarchy of classes |
The table includes all classes above and classes immediately below the current class. |
Cluster id | Level | Cluster label | #P |
---|---|---|---|
1 | 4 | ECONOMICS//EDUCATION & EDUCATIONAL RESEARCH//PSYCHOL | 3876184 |
154 | 3 | PSYCHIATRY//ALEXITHYMIA//PSYCHIAT | 62481 |
207 | 2 | PSYCHIATRY//ANTIDEPRESSANTS//DEPRESSION | 21074 |
10431 | 1 | MOCLOBEMIDE//ATYPICAL DEPRESSION//BROFAROMINE | 1064 |
Terms with highest relevance score |
rank | Term | termType | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|---|
1 | MOCLOBEMIDE | authKW | 1259082 | 11% | 39% | 113 |
2 | ATYPICAL DEPRESSION | authKW | 615281 | 5% | 40% | 53 |
3 | BROFAROMINE | authKW | 322971 | 2% | 49% | 23 |
4 | PHENELZINE | authKW | 217880 | 3% | 28% | 27 |
5 | MONOAMINE OXIDASE INHIBITORS | authKW | 151095 | 4% | 12% | 43 |
6 | SELEGILINE TRANSDERMAL SYSTEM | authKW | 147583 | 1% | 86% | 6 |
7 | RIMA | authKW | 119560 | 1% | 42% | 10 |
8 | PIRLINDOLE | authKW | 108159 | 1% | 54% | 7 |
9 | MOOD REACTIVITY | authKW | 102487 | 0% | 71% | 5 |
10 | TYRAMINE PRESSOR TEST | authKW | 91829 | 0% | 80% | 4 |
Web of Science journal categories |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | Psychiatry | 27097 | 57% | 0% | 607 |
2 | Pharmacology & Pharmacy | 5948 | 44% | 0% | 468 |
3 | Psychology, Clinical | 1511 | 9% | 0% | 94 |
4 | Clinical Neurology | 1347 | 17% | 0% | 177 |
5 | Neurosciences | 712 | 17% | 0% | 182 |
6 | Chemistry, Medicinal | 123 | 4% | 0% | 42 |
7 | Psychology | 86 | 2% | 0% | 26 |
8 | Chemistry, Analytical | 14 | 3% | 0% | 34 |
9 | Toxicology | 13 | 2% | 0% | 20 |
10 | Medicine, Legal | 12 | 0% | 0% | 5 |
Address terms |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | DEP S UNIT PSYCHIAT | 57394 | 0% | 100% | 2 |
2 | NEUROCHEM UNIT | 41849 | 2% | 8% | 18 |
3 | BIOTRIAL | 38261 | 0% | 67% | 2 |
4 | ABT MEDWISS PHARMAKOVIGILANZ | 28697 | 0% | 100% | 1 |
5 | ANHUI CHINESE MED DEV | 28697 | 0% | 100% | 1 |
6 | BIOPHARMACEUT SCI BIOSTAT | 28697 | 0% | 100% | 1 |
7 | BOTULINUM TREATMENT DYSTONIA PROGRAM | 28697 | 0% | 100% | 1 |
8 | BRAIN NETWORK ACTIVAT PROGRAM | 28697 | 0% | 100% | 1 |
9 | CARL GUSTAV CARUS KRANKENHAUS | 28697 | 0% | 100% | 1 |
10 | CONSULTANCY CONTRACT | 28697 | 0% | 100% | 1 |
Journals |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | JOURNAL OF CLINICAL PSYCHIATRY | 24607 | 7% | 1% | 78 |
2 | JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY | 21434 | 4% | 2% | 45 |
3 | JOURNAL OF AFFECTIVE DISORDERS | 10747 | 5% | 1% | 56 |
4 | CLINICAL NEUROPHARMACOLOGY | 6309 | 2% | 1% | 23 |
5 | PHARMACOPSYCHIATRY | 5697 | 2% | 1% | 20 |
6 | PSYCHOPHARMACOLOGY BULLETIN | 5167 | 2% | 1% | 18 |
7 | INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY | 4491 | 2% | 1% | 17 |
8 | PSYCHIATRIC ANNALS | 4177 | 2% | 1% | 19 |
9 | PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY | 3340 | 2% | 0% | 24 |
10 | ACTA PSYCHIATRICA SCANDINAVICA | 2931 | 2% | 0% | 25 |
Author Key Words |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | MOCLOBEMIDE | 1259082 | 11% | 39% | 113 | Search MOCLOBEMIDE | Search MOCLOBEMIDE |
2 | ATYPICAL DEPRESSION | 615281 | 5% | 40% | 53 | Search ATYPICAL+DEPRESSION | Search ATYPICAL+DEPRESSION |
3 | BROFAROMINE | 322971 | 2% | 49% | 23 | Search BROFAROMINE | Search BROFAROMINE |
4 | PHENELZINE | 217880 | 3% | 28% | 27 | Search PHENELZINE | Search PHENELZINE |
5 | MONOAMINE OXIDASE INHIBITORS | 151095 | 4% | 12% | 43 | Search MONOAMINE+OXIDASE+INHIBITORS | Search MONOAMINE+OXIDASE+INHIBITORS |
6 | SELEGILINE TRANSDERMAL SYSTEM | 147583 | 1% | 86% | 6 | Search SELEGILINE+TRANSDERMAL+SYSTEM | Search SELEGILINE+TRANSDERMAL+SYSTEM |
7 | RIMA | 119560 | 1% | 42% | 10 | Search RIMA | Search RIMA |
8 | PIRLINDOLE | 108159 | 1% | 54% | 7 | Search PIRLINDOLE | Search PIRLINDOLE |
9 | MOOD REACTIVITY | 102487 | 0% | 71% | 5 | Search MOOD+REACTIVITY | Search MOOD+REACTIVITY |
10 | TYRAMINE PRESSOR TEST | 91829 | 0% | 80% | 4 | Search TYRAMINE+PRESSOR+TEST | Search TYRAMINE+PRESSOR+TEST |
Core articles |
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c: (1) Number of references referring to publications in the class. (2) Share of total number of active references referring to publications in the class. (3) Age of the article. New articles get higher score than old articles. (4) Citation rate, normalized to year. |
Rank | Reference | # ref. in cl. |
Shr. of ref. in cl. |
Citations |
---|---|---|---|---|
1 | PAE, CU , TARWANI, H , MARKS, DM , MASAND, PS , PATKAR, AA , (2009) ATYPICAL DEPRESSION A COMPREHENSIVE REVIEW.CNS DRUGS. VOL. 23. ISSUE 12. P. 1023-1037 | 53 | 76% | 23 |
2 | BONNET, U , (2003) MOCLOBEMIDE: THERAPEUTIC USE AND CLINICAL STUDIES.CNS DRUG REVIEWS. VOL. 9. ISSUE 1. P. 97-140 | 87 | 49% | 79 |
3 | LOTUFO-NETO, F , TRIVEDI, M , THASE, ME , (1999) META-ANALYSIS OF THE REVERSIBLE INHIBITORS OF MONOAMINE OXIDASE TYPE A MOCLOBEMIDE AND BROFAROMINE FOR THE TREATMENT OF DEPRESSION.NEUROPSYCHOPHARMACOLOGY. VOL. 20. ISSUE 3. P. 226 -247 | 62 | 77% | 82 |
4 | THASE, ME , (2009) ATYPICAL DEPRESSION: USEFUL CONCEPT, BUT IT'S TIME TO REVISE THE DSM-IV CRITERIA.NEUROPSYCHOPHARMACOLOGY. VOL. 34. ISSUE 13. P. 2633 -2641 | 40 | 77% | 27 |
5 | FULTON, B , BENFIELD, P , (1996) MOCLOBEMIDE - AN UPDATE OF ITS PHARMACOLOGICAL PROPERTIES AND THERAPEUTIC USE.DRUGS. VOL. 52. ISSUE 3. P. 450-474 | 61 | 69% | 67 |
6 | FITTON, A , FAULDS, D , GOA, KL , (1992) MOCLOBEMIDE - A REVIEW OF ITS PHARMACOLOGICAL PROPERTIES AND THERAPEUTIC USE IN DEPRESSIVE-ILLNESS.DRUGS. VOL. 43. ISSUE 4. P. 561-596 | 71 | 62% | 109 |
7 | THASE, ME , TRIVEDI, MH , RUSH, AJ , (1995) MAOIS IN THE CONTEMPORARY TREATMENT OF DEPRESSION.NEUROPSYCHOPHARMACOLOGY. VOL. 12. ISSUE 3. P. 185-219 | 66 | 58% | 122 |
8 | WIMBISCUS, M , KOSTENKO, O , MALONE, D , (2010) MAO INHIBITORS: RISKS, BENEFITS, AND LORE.CLEVELAND CLINIC JOURNAL OF MEDICINE. VOL. 77. ISSUE 12. P. 859 -+ | 33 | 61% | 36 |
9 | HENKEL, V , MERGL, R , ALLGAIER, AK , KOHNEN, R , MOLLER, HJ , HEGERL, U , (2006) TREATMENT OF DEPRESSION WITH ATYPICAL FEATURES: A META-ANALYTIC APPROACH.PSYCHIATRY RESEARCH. VOL. 141. ISSUE 1. P. 89-101 | 38 | 58% | 52 |
10 | ANGST, J , GAMMA, A , BENAZZI, F , SILVERSTEIN, B , AJDACIC-GROSS, V , EICH, D , ROSSLER, W , (2006) ATYPICAL DEPRESSIVE SYNDROMES IN VARYING DEFINITIONS.EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE. VOL. 256. ISSUE 1. P. 44 -54 | 30 | 70% | 60 |
Classes with closest relation at Level 1 |